AUPP437698A0 - Methods for treatment of coronary, carotid and other vascular disease - Google Patents

Methods for treatment of coronary, carotid and other vascular disease

Info

Publication number
AUPP437698A0
AUPP437698A0 AUPP4376A AUPP437698A AUPP437698A0 AU PP437698 A0 AUPP437698 A0 AU PP437698A0 AU PP4376 A AUPP4376 A AU PP4376A AU PP437698 A AUPP437698 A AU PP437698A AU PP437698 A0 AUPP437698 A0 AU PP437698A0
Authority
AU
Australia
Prior art keywords
treatment
methods
carotid
coronary
vascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP4376A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baumgart Karl
Original Assignee
Baumgart Karl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baumgart Karl filed Critical Baumgart Karl
Priority to AUPP4376A priority Critical patent/AUPP437698A0/en
Publication of AUPP437698A0 publication Critical patent/AUPP437698A0/en
Priority to US09/736,029 priority patent/US6475518B1/en
Priority to AU45919/99A priority patent/AU757293B2/en
Priority to EP99928901A priority patent/EP1093363B1/en
Priority to AT99928901T priority patent/ATE345115T1/de
Priority to HK01107443.7A priority patent/HK1037864B/en
Priority to JP2000557825A priority patent/JP4651816B2/ja
Priority to NZ509504A priority patent/NZ509504A/en
Priority to EP06023648.6A priority patent/EP1754472B1/en
Priority to ES06023648.6T priority patent/ES2514469T3/es
Priority to PCT/AU1999/000528 priority patent/WO2000001378A1/en
Priority to DE69934010T priority patent/DE69934010T2/de
Priority to CA2684402A priority patent/CA2684402C/en
Priority to ES99928901T priority patent/ES2278449T3/es
Priority to CA2336593A priority patent/CA2336593C/en
Priority to JP2010074109A priority patent/JP5335726B2/ja
Priority to JP2013076511A priority patent/JP2013147504A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AUPP4376A 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease Abandoned AUPP437698A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease
US09/736,029 US6475518B1 (en) 1998-06-30 1999-06-20 Methods and compositions for treatment of disorders associated with chlamydia and similar bacterial infection
CA2336593A CA2336593C (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
EP06023648.6A EP1754472B1 (en) 1998-06-30 1999-06-30 Compositions for treatment of disorders associated with chlamydia
ES06023648.6T ES2514469T3 (es) 1998-06-30 1999-06-30 Composiciones para el tratamiento de trastornos asociados con Chlamydia
AT99928901T ATE345115T1 (de) 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
HK01107443.7A HK1037864B (en) 1998-06-30 1999-06-30 Compositions for treatment of disorders associated with chlamydia
JP2000557825A JP4651816B2 (ja) 1998-06-30 1999-06-30 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
NZ509504A NZ509504A (en) 1998-06-30 1999-06-30 Combination antibiotics for treatment of disorders associated with chlamydial and similar bacterial infection
AU45919/99A AU757293B2 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
EP99928901A EP1093363B1 (en) 1998-06-30 1999-06-30 Compositions for treatment of disorders associated with chlamydia
PCT/AU1999/000528 WO2000001378A1 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
DE69934010T DE69934010T2 (de) 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
CA2684402A CA2684402C (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
ES99928901T ES2278449T3 (es) 1998-06-30 1999-06-30 Composiciones para el tratamiento de trastornos asociados a la chlamydia.
JP2010074109A JP5335726B2 (ja) 1998-06-30 2010-03-29 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2013076511A JP2013147504A (ja) 1998-06-30 2013-04-02 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease

Publications (1)

Publication Number Publication Date
AUPP437698A0 true AUPP437698A0 (en) 1998-07-23

Family

ID=3808619

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPP4376A Abandoned AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease
AU45919/99A Expired AU757293B2 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU45919/99A Expired AU757293B2 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Country Status (10)

Country Link
US (1) US6475518B1 (enExample)
EP (2) EP1754472B1 (enExample)
JP (3) JP4651816B2 (enExample)
AT (1) ATE345115T1 (enExample)
AU (2) AUPP437698A0 (enExample)
CA (2) CA2684402C (enExample)
DE (1) DE69934010T2 (enExample)
ES (2) ES2278449T3 (enExample)
NZ (1) NZ509504A (enExample)
WO (1) WO2000001378A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
EP1166117A2 (en) * 1999-03-19 2002-01-02 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6623757B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Antibiotic composition
EP1265608B1 (en) * 2000-03-22 2008-10-29 Pharmacia & Upjohn Company LLC Oxazolidinone tablet formulation
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
IT1318459B1 (it) * 2000-04-11 2003-08-25 Zambon Spa Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
EP1262185A1 (en) * 2001-05-30 2002-12-04 New Pharma Research Sweden AB Synergistic antibiotic compositions
EP1406700A1 (en) * 2001-07-06 2004-04-14 Sucampo AG Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
CA2478121A1 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US20040126414A1 (en) * 2002-12-12 2004-07-01 Michaelis Arthur F. Methods and compositions for treating and preventing ear infections
US20040176404A1 (en) * 2002-12-12 2004-09-09 Sayada Chalom B. Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
RU2254123C2 (ru) * 2003-08-11 2005-06-20 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Препарат для лечения гемобартонеллеза кошек и способ его применения
WO2005027961A2 (en) * 2003-09-23 2005-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Chlamydia pmpd autotransporter and its role as adhesin
JP2007520495A (ja) 2004-02-06 2007-07-26 ボロディー トーマス ユリウス 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
JP5047797B2 (ja) * 2004-09-30 2012-10-10 コヴァロン・テクノロジーズ・インコーポレーテッド 非接着性の弾性ゼラチンマトリックス
EP1815869A4 (en) * 2004-11-24 2011-04-06 Nanocarrier Co Ltd PROCESS FOR CHANGING THE MORPHOLOGY OF BLOCK COPOLYMERS
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2816276A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
US8647673B2 (en) * 2007-07-24 2014-02-11 Wayne State University Nanoparticles for imaging and treating chlamydial infection
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
DE112010004110T8 (de) 2009-10-22 2012-12-06 Thomas Julius Borody Neue parasitentherapie
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
BR122014009845A2 (pt) 2010-04-26 2015-12-29 Salix Pharmaceuticals Ltd usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa
BR112013014827A2 (pt) 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas
JP6146922B2 (ja) * 2011-08-16 2017-06-14 ピュラック バイオケム ビー． ブイ． 発酵ブロス処理にとって有用な、塩化水素酸を用いた沈殿によるカルボン酸のそれらのマグネシウム塩からの回収
NZ704014A (en) 2012-07-27 2017-10-27 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA2997671A1 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
CN111757732A (zh) * 2018-02-01 2020-10-09 消化系统疾病中心 用于治疗感染性动脉疾病和相关病状的组合物
RU2684728C1 (ru) * 2018-05-21 2019-04-12 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе
CN115867288A (zh) * 2020-03-27 2023-03-28 维克多瑞有限公司 用于治疗呼吸系统病症的组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588550A (en) 1897-08-24 Alarm-clock
GB1463550A (en) 1974-08-06 1977-02-02 Bodrero G Pharmaceutical composition
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI883067A7 (fi) * 1988-06-27 1989-12-28 Labsystems Oy Foerfarande foer behandling av koronarkaerlsjukdom.
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6080757A (en) * 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US5811121A (en) 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物

Also Published As

Publication number Publication date
WO2000001378A1 (en) 2000-01-13
EP1754472B1 (en) 2014-07-23
AU757293B2 (en) 2003-02-13
CA2336593C (en) 2010-06-29
EP1754472A2 (en) 2007-02-21
JP2002519374A (ja) 2002-07-02
EP1093363A1 (en) 2001-04-25
JP5335726B2 (ja) 2013-11-06
HK1037864A1 (en) 2002-02-22
EP1093363A4 (en) 2003-09-24
CA2684402C (en) 2012-10-30
JP2010174030A (ja) 2010-08-12
CA2684402A1 (en) 2000-01-13
CA2336593A1 (en) 2000-01-13
ATE345115T1 (de) 2006-12-15
DE69934010D1 (de) 2006-12-28
EP1754472A3 (en) 2009-08-26
JP2013147504A (ja) 2013-08-01
AU4591999A (en) 2000-01-24
DE69934010T2 (de) 2007-06-21
ES2278449T3 (es) 2007-08-01
EP1093363B1 (en) 2006-11-15
ES2514469T3 (es) 2014-10-28
NZ509504A (en) 2004-04-30
JP4651816B2 (ja) 2011-03-16
US6475518B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
EP1754472A3 (en) Compositions for treatment of disorders associated with chlamydia
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
CA2263972A1 (en) 6-o-substituted ketolides having antibacterial activity
IL183296A0 (en) Multivalent vaccine composition with mixed carrier
WO2003004509A3 (en) C12 modified erythromycin macrolides and ketolides having antibacterial activity
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
WO2000044761A3 (en) Ketolide antibiotics
PT1021456E (pt) Derivados macrociclicos de eritromicinas a e b de anel de 13 membros
CA2359354A1 (en) Medicament for the treatment, prevention and diagnosis of infection due to chlamydia pneumoniae
DE69631609D1 (en) Tricyclische erythromycinderivate
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
HUP0004579A2 (hu) Antibakteriális hatású, a 3'-N-pozícióban módosított szerkezetű 6-0-szubsztituált-eritromicin-ketolid-származékok és ezeket tartalmazó gyógyszerkészítmények
WO1998019670A3 (en) Combination therapy of hepatitis C infections
MX9708611A (es) Compuestos de dialquiltiacumicina.
EP0775745A3 (en) Cathepsin G-inhibiting aptamers
DK1007530T3 (da) 6-O-substituerede erythromycinforbindelser samt fremgangsmåde til fremstilling heraf
CA2380455A1 (en) 9a-azalides with antibacterial activity
ATE286893T1 (de) 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2000010998A3 (en) Pyridone antibiotic with improved safety profile
ZA971036B (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections.
WO2002057281A3 (en) Aminoglycosides as antibiotics
SE9902674D0 (sv) New composition
WO1998014567A3 (en) Methods and compositions for inhibiting bacterial growth
CA2564020A1 (en) 6-o-substituted ketolides having antibacterial activity

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 4591999

Country of ref document: AU